Is C15 effective for improving renal function or preventing kidney disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

C15 (Pentadecanoic Acid) for Kidney Health

C15 (pentadecanoic acid) is not recommended for improving renal function or preventing kidney disease, as there is no evidence supporting its efficacy for kidney-specific outcomes, and it is not mentioned in current kidney disease management guidelines.

Evidence Assessment

The 2024 KDIGO guidelines 1, 2, 3 provide comprehensive, evidence-based recommendations for CKD management but make no mention of C15 or pentadecanoic acid as a therapeutic intervention for kidney health. These guidelines represent the highest quality evidence for CKD management and should guide clinical decision-making.

What the Guidelines Actually Recommend for Kidney Health:

For CKD progression prevention:

  • SGLT2 inhibitors for patients with proteinuria (with or without diabetes)
  • RAAS inhibitors for blood pressure control and proteinuria management
  • Finerenone for patients with type 2 diabetes and CKD
  • GLP-1 receptor agonists for kidney-protective effects 3

For cardiovascular risk reduction in CKD:

  • Statins or statin/ezetimibe combinations for adults ≥50 years with eGFR <60 ml/min per 1.73 m² 1, 2
  • Mediterranean-style diet as an adjunct to lipid-modifying therapy 1

C15 Research Context

While research on C15 exists 4, 5, 6, 7, 8, these studies focus on:

  • Cell-based assays showing anti-inflammatory and antiproliferative activities 5, 6
  • Cardiovascular associations (hypertension, cardiometabolic disease) 8
  • General metabolic effects 4

Critical limitation: None of these studies directly evaluate C15's effect on kidney function, CKD progression, or kidney-specific outcomes. The research on C15 and kidney health is essentially non-existent.

Why This Matters:

The one study mentioning kidney-related outcomes 9 evaluated probiotics for CKD, not C15. This is entirely unrelated to pentadecanoic acid supplementation.

Clinical Bottom Line

Use evidence-based therapies with proven kidney benefits:

  • SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)
  • RAAS inhibitors (ACE inhibitors or ARBs)
  • Finerenone for diabetic CKD
  • Statins for cardiovascular protection 1, 3

Do not substitute unproven supplements like C15 for guideline-directed medical therapy. The absence of C15 from KDIGO 2024 guidelines—despite their comprehensive review of CKD interventions—speaks volumes about the lack of kidney-specific evidence.

Common Pitfall to Avoid:

Do not extrapolate C15's potential cardiovascular or anti-inflammatory effects to assume kidney benefits. Kidney disease requires interventions with demonstrated effects on renal outcomes (eGFR decline, proteinuria, ESRD progression), which C15 lacks entirely.

References

Research

KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.